Novartis AG ADR (NVS) News
Filter NVS News Items
NVS News Results
|Loading, please wait...|
NVS News Highlights
- For NVS, its 30 day story count is now at 47.
- Over the past 24 days, the trend for NVS's stories per day has been choppy and unclear. It has oscillated between 1 and 9.
- The most mentioned tickers in articles about NVS are DRUG, CC and AG.
Latest NVS News From Around the Web
Below are the latest news stories about NOVARTIS AG that investors may wish to consider to help them evaluate NVS as an investment opportunity.
Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.20 on 13th of...
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like a
Novartis ( VTX:NOVN ) Full Year 2022 Results Key Financial Results Revenue: US$51.8b (down 2.0% from FY 2021). Net...
Novartis AG (NYSE:NVS) Q4 2022 Earnings Call Transcript February 1, 2023 Operator: Good morning and good afternoon, and welcome to the Novartis Q4 2022 Results Release Conference Call and Live Webcast. Please note that during the presentation all participants will be in a listen-only mode and the conference is being recorded. After the presentation, there […]
Highlights from Fortune's dinner in Davos.
GSK stock and NVO stock rose Wednesday, though both beat forecasts. Novartis stock skidded on lighter-than-expected sales.
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
NVS earnings call for the period ending December 31, 2022.
Novartis AG (NYSE: NVS) has reported Q4 core EPS of $1.52 compared to $1.40 a year ago, beating the consensus of $1.44. Net sales were $12.69 billion, down 4% Y/Y or up 3% at constant currency (CC), missing the consensus of $13.13 billion. Core operating income was $4 billion (+6%, +15% cc), driven by higher sales and productivity, including initial savings from the previously announced streamlined organizational model. Related: Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalm
Bloomberg's Joe Easton has a rundown of the stocks to keep an eye on today, including pharmaceutical firms Novartis, Novo Nordisk and GSK, Spanish bank BBVA, and Ladbrokes owner Entain. He speaks on Bloomberg Television. Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com Connect with us on... Twitter: https://twitter.com/business Facebook: https://www.facebook.com/bloombergbusiness/ Instagram: https://www.instagram.com/quicktake/?hl=en